Brief: Caribou Biosciences Says Expects To Initiate Pivotal Trial For Cb-010 In H2 2025
03/06/2024 24:02
June 2 (Reuters) - Caribou Biosciences Inc CRBU.O :
* CARIBOU BIOSCIENCES PRESENTS ENCOURAGING CLINICAL DATA
FROM
CB-010 ANTLER PHASE 1 TRIAL IN SECOND-LINE LBCL PATIENTS AT THE
2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
* CARIBOU BIOSCIENCES - EXPECTS TO INITIATE PIVOTAL TRIAL
FOR
CB-010 IN H2 2025, UPON CONFIRMATION OF IMPROVED OUTCOMES IN
PARTIALLY HLA MATCHED COHORT
Source text for Eikon: ID:nGNX4f2ZQ5
Further company coverage: CRBU.O
((Reuters.Briefs@thomsonreuters.com;))